12:00 AM
May 20, 2013
 |  BC Week In Review  |  Clinical News  |  Clinical Results

ArteFill: Phase III data

A double-blind, U.S. Phase III trial in about 177 patients with moderate to severe atrophic acne scars showed that ArteFill met the primary endpoint of a greater response rate, defined as a 2-point improvement on the 4-point ASRS for >=50% of scars treated, at 6 months...

Read the full 206 word article

User Sign in

Trial Subscription

Get a 4-week free trial subscription to BioCentury Week In Review

Article Purchase

$35 USD
More Info >